Abstract
With advances in cancer screening and treatment, there is a growing population of cancer survivors who may develop subsequent primary cancers. While hereditary cancer syndromes account for only a portion of multiple cancer cases, we sought to explore the role of common genetic variation in susceptibility to multiple primary tumors. We conducted a cross-ancestry genome-wide association study (GWAS) and transcriptome-wide association study (TWAS) of 10,983 individuals with multiple primary cancers, 84,475 individuals with single cancer, and 420,944 cancer-free controls from two large-scale studies.
Our GWAS identified six lead variants across five genomic regions that were significantly associated (P<5×10-8) with the risk of developing multiple primary tumors (overall and invasive) relative to cancer-free controls (at 3q26, 8q24, 10q24, 11q13.3, and 17p13). We also found one variant significantly associated with multiple cancers when comparing to single cancer cases (at 22q13.1). Multi-tissue TWAS detected associations with genes involved in telomere maintenance in two of these regions (ACTRT3 in 3q26 and SLK and STN1 in 10q24) and the development of multiple cancers. Additionally, the TWAS also identified several novel genes associated with multiple cancers, including two immune-related genes, IRF4 and TNFRSF6B. Telomere maintenance and immune dysregulation emerge as central, common pathways influencing susceptibility to multiple cancers. These findings underscore the importance of exploring shared mechanisms in carcinogenesis, offering insights for targeted prevention and intervention strategies.
Competing Interest Statement
L.C.S. has received research grant funding from AstraZeneca, awarded directly to her institution that is unrelated to this work. J.S.W. is a non-employee co-founder of Avail Bio, and has served as an expert witness for legal matters unrelated to this work. No disclosures were reported for other authors.
Funding Statement
This work was supported by the National Institutes of Health (grant numbers K07CA188142, K24CA169004, R01CA088164, R01CA201358, R25CA112355, RC2AG036607, and U01CA127298). Support for participant enrollment, survey administration, and biospecimen collection for the Research Program on Genes, Environment, and Health was provided by the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, and Kaiser Permanente National and regional community benefit programs. Data from the UK Biobank resource was obtained under application number 14105. LK is supported by funding from the NCI (R00CA246076) and REG is supported by a Young Investigator Award from the Prostate Cancer Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the UK Biobank gave ethical approval for this work Ethics committee/IRB of the Kaiser Permanente Northern California gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The UK Biobank is an open-access data resource, and the data is available from the UK Biobank access portal at https://www.ukbiobank.ac.uk. This research was conducted with approved access to UK Biobank data under application number 14105. The Kaiser Permanente Research Bank data are available via dbGaP (phs002809.v1.p1). Results generated from this work are included in the published article or Supplementary Materials. All additional data corresponding to the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.
